Vaxcyte, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Vaxcyte announced positive topline results from OPUS-1, a pivotal Phase 3 trial of VAX-31 (31-valent pneumococcal conjugate vaccine) in 4,047 healthy US adults, meeting all prespecified primary immunogenicity endpoints with a safety profile similar to PCV20 and PCV21. The company completed concurrent equity and convertible debt offerings in October 2026, raising $1.15B gross proceeds ($1.1B net), bringing pro forma cash to $3.4B as of September 30, 2026. OPUS-2 and OPUS-3 Phase 3 results are expected in H1 2027, supporting a planned Biologics License Application submission in H1 2028.
Why this rating
Pivotal trial success + major financing substantially derisks lead program valued at ~$3.7B market cap. Significant but not transformational—regulatory/commercial execution risks remain.
Price action (we called it positive)
before filing · preread $65.68 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.